GSK sees sales beat forecasts thanks to shingles jab and HIV drugs
The pharmaceutical giant saw revenues drop 8% in the first quarter, but this was better than feared.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Drugs giant GSK has posted better-than-forecast revenues for the first quarter thanks to strong sales of its shingles vaccine and HIV medicines.
The FTSE 100 group saw earnings fall 15% on a constant currency basis to £2.1 billion in the first quarter as revenues dropped 8% to £7 billion after sales of its Covid-19 treatment Xevudy fell back from strong sales seen a year earlier.
But despite this, its revenues beat expectations thanks to a 11% leap in sales of its Shingrix jab for shingles, to £833 million over the first three months of 2023.
Its HIV vaccines and treatments also gave the group a boost, with sales up 15% thanks to strong demand for its oral two-drug regimen and long-acting drugs, as well as price increases in the US.
GSK stuck by its guidance for full year underlying earnings to rise by between 10% to 12% on sales between 6% and 8% higher.
But it said earnings will be lower in the first half due to expected drug launches pushing up costs, with second half operating profits set to be higher.
GSK, which spun off its consumer healthcare business, named Haleon, last year, said that with Covid-19 sales stripped out, turnover lifted 10% to £6.8 billion.
Emma Walmsley, chief executive of GSK, said: “We have made a strong start to 2023, with excellent performance across vaccines, specialty and general medicines.
“We are very focused on our upcoming launches, including our potential RSV older adult vaccine, and on continuing to strengthen our pipeline.”
It is racing against rivals to launch an inoculation for respiratory syncytial virus (RSV), which causes 8,000 deaths in the UK alone each year.
GSK hopes to launch its RSV jab later this year.
The latest figures come as hundreds of workers at GSK are set to stage a series of walkouts in May in a dispute over pay.
Unite said last week that 750 of its members have voted for strike action after rejecting a 6% pay offer and a one-off lump sum of £1,300, describing it as “significantly below” inflation.